By Connor Hart
Medtronic received approval for its OmniaSecure defibrillation lead for placement within the right ventricle, from the Food and Drug Administration.
The medical technology company said Friday that the device, with a 1.6 millimeter diameter, is the smallest defibrillation lead. It was indicated for patients ages 12 and up, including those with smaller anatomies.
The lead connects to an implantable defibrillator, or a device that applies an electric charge or current to the heart, to restore a normal heartbeat.
Medtronic said its OmniaSecure device can be used to treat potentially life-threatening conditions including ventricular tachyarrhythmias, a heart rhythm disorder where the heart's lower chambers beat too fast, and ventricular fibrillation, an arrhythmia in which the heart's ventricles quiver instead of contracting normally.
While the device was approved for use within the right ventricle, the company is studying placing the device in the left bundle branch area. This placement, which still requires FDA approval, has the potential to enable physiologic pacing to more closely mimic the heart's natural conduction system, it said.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
April 25, 2025 18:12 ET (22:12 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。